Terapevticheskii Arkhiv · Sep 17, 2026

Resolution of the Council of Experts “The role of pioglitazone in the secondary prevention of ischemic stroke and transient ischemic attack in adult patients with type 2 diabetes mellitus, prediabetes, or insulin resistance”

By Tanashyan MM, Shestakova MV, Galstyan GR et al.

On April 3, 2026, an Advisory Board meeting was held in Moscow with the participation of leading neurologists and endocrinologists. The meeting was dedicated to assessing the evidence base and formulating a position on the role of pioglitazone in the secondary prevention of ischemic stroke and transient ischemic attack in patients with impaired glucose metabolism. During the meeting, the results of key randomized clinical trials (PROactive, IRIS), meta-analyses, and data from observational studies were analyzed. The experts reviewed the efficacy, safety, optimal timing of initiation, dosing regimens, and combination therapy with pioglitazone. Based on the discussion, a consensus position was formulated on the advisability of including pioglitazone in clinical guidelines for the secondary prevention of ischemic stroke and transient ischemic attack in patients with type 2 diabetes mellitus, prediabetes, or laboratory-confirmed insulin resistance. Target patient groups, exclusion criteria, and practical aspects of therapy monitoring were defined.

doi.org/10.26442/00403660.2026.10.203854Industry & policy

AgingResearch.News